Overview

Safety and Efficacy of AIV001 on Scar Formation and Keloid Recurrence Following Keloidectomy

Status:
Not yet recruiting
Trial end date:
2022-09-01
Target enrollment:
Participant gender:
Summary
To evaluate how safe and effective AIV001 treatment is on scar formation and/or keloid recurrence following keloidectomy.
Phase:
Phase 1
Details
Lead Sponsor:
AiViva BioPharma, Inc.